Venus Concept (NASDAQ:VERO) Shares Down 2.3% – Here’s Why

Venus Concept Inc. (NASDAQ:VERO)’s share price fell 2.3% on Tuesday . The stock traded as low as $2.06 and last traded at $2.14. 34,293 shares were traded during trading, a decline of 83% from the average session volume of 205,508 shares. The stock had previously closed at $2.19.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Venus Concept in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Venus Concept currently has a consensus rating of “Sell”.

Venus Concept Stock Down 2.3%

The company has a quick ratio of 0.71, a current ratio of 1.10 and a debt-to-equity ratio of 5.72. The stock has a market cap of $3.04 million, a PE ratio of -0.04 and a beta of 0.05. The business has a 50 day moving average price of $2.32 and a 200 day moving average price of $2.46.

Venus Concept (NASDAQ:VERO) last issued its earnings results on Thursday, August 14th. The company reported ($8.03) EPS for the quarter, topping analysts’ consensus estimates of ($9.72) by $1.69. Venus Concept had a negative return on equity of 871.77% and a negative net margin of 68.77%.The firm had revenue of $15.69 million for the quarter, compared to the consensus estimate of $14.01 million.

Venus Concept Company Profile

Venus Concept Inc, a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; Venus Versa Pro; and Venus Viva and Venus Viva MD, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin.